Search
At Dana-Farber Cancer Institute in Boston, President & CEO Ben Ebert and Professor and Investigator Cigall Kadoch discuss the latest trends in cancer research
They discuss recent advances, what's ahead, Cigall's work in epigenetics, and how a new hospital will be purpose built for patients with the best new technologies in clinical research. Chapters Cancer research advances - 1:14 Cigall's work in epigenetics - 4:33 Dana-Farber's future new hospital - 9:29 AI centered approaches - 14:15 Looking ahead - 16:51
2 days ago
Catching up on the latest in food allergy science at FASI's 10-year anniversary research summit in Kendall Square
Board members Lesley Solomon and Eric Edwards discuss the work that FASI has been doing over the last decade and how science is leading to new targets that could potentially have broad impact on many types of allergies at once.
Oct 6
Massachusetts Life Sciences Center announced $40 million in tax incentive funding for local life sciences companies last week
Interim President & CEO Elizabeth Graham also describes a new program for early stage companies that is being announced today: Access and Accelerate Grants.
Oct 5
Christof Kloepper, CEO of Basel Area Business & Innovation, shares the history of life sciences in Basel and describes the investments in infrastructure that have been made over recent years
He describes how while Basel started out as a pharma town with large companies, more and more smaller biotech companies have made it an innovation area today. Plus, the importance of the various tech parks that have arisen, and his take on the state of biotech today. Coverage brought to you by
Oct 2
Swiss Nordic Bio 2026: Pareto Securities' Equity Research Analyst Filip Wiberg shares his take on three companies he covers in the biotech and MedTech spaces
He discusses Devyser Diagnostics, XVIVO, and ArcticZymes Technologies. Coverage brought to you by
Oct 1
Swiss Nordic Bio 2026: Pareto Securities' Dan Akschuti shares his take on the environment in the room and around biotech
He cites strong business development activity from pharmas in the area, many deals of which have gone to companies in the area. Coverage brought to you by
Oct 1
Swiss Nordic Bio 2026: Pareto Securities analysts Chien-Hsun Lee shares takeaways from the conference and highlight companies of focus
He discusses Circio, AlzeCure, Pilatus Biosciences, and Amphilix. Coverage brought to you by
Sep 30
Swiss Nordic Bio 2026: Business Sweden CEO Jan Larsson describes the momentum and partnership that these two regions share in biopharma
He describes the origins of the conference and the deals that can come out of it. Coverage brought to you by
Sep 30
Barclays Biotech Analyst Lukas Shumway shares his take on the current state of biotech and comments on companies he covers in the news
He discusses recent news regarding Cellectis, Alpha Tau Medical, and Immunome.
Sep 30
From Basel: Forty51 Ventures was formed in Basel four years ago and has a company building model - they look globally, but believe that having the pharma company pipeline in Basel is an advantage
Co-Founder & Partner Sascha Oliver Bucher describes the firm and investments it has been making, and shares his thoughts on the VC ecosystem in Europe. Coverage brought to you by
Sep 28
HCW 2026: H.C. Wainwright & Co. Senior Biotech Analyst Andres Maldonado shares his take on the latest in oncology
He discusses the big year oncology has had, including in the RAS space, and highlights key catalysts he will be watching throughout the remainder of 2026. Coverage brought to you by
Sep 15
HCW 26: H.C. Wainwright Senior Biotechnology Analyst Mitchell Kapoor touches on current biotech sentiment, the cardiovascular space, in vivo CAR-T, and a pancreatic study to watch
Based on his analysis, a higher percentage of biotech companies have been trading up on positive data than the previous year. He also discusses going back to the drawing board on cardiovascular targets, in vivo CAR-T programs, and his key catatalysts to watch throughout the rest of the year. Coverage brought to you by
Sep 14
HCW 2026: H.C. Wainwright & Co.'s Vice Chair and President of Capital Markets Richard Gormley believes the elements (M&A, IPOs opening up, other financing opportunities) are still ripe for biotech
He discusses M&A, which he believes can continue, and the IPO market that finally opened up in 2026. Plus, how positive headlines like Moderna & Merck's cancer vaccine have been causing investors to look at the sector. Coverage brought to you by
Sep 14
UC Berkeley's Gokul Upadhyayula and Eric Betzig are building AI to interpret detailed movies of living cells captured by their MOSAIC microscope
The work could help guide drug discovery and development by revealing how disease disrupts cells.
Sep 8
Pareto Securities Healthcare Conference: Pareto's Dan Akschuti highlights the innovation coming out of the Nordics region and companies that have filings in front of FDA
He says that capital is returning to the sector and that investors have been doing more scientific due diligence recenetly. Plus, the impact of AI on biotech.
Sep 2
Congressman Jake Auchincloss discusses the economic impact of biotech, global competition, and efforts he is taking to solidify funding, modernize regulation, and keep the United States on top
Interviewed by MassBio CEO Kendalle Burlin O'Connell, Congressman Auchincloss of Massachusetts describes the impact he believes a tightening of funding for basic research is having on our industry and measures he would take to bolster innovative research. He advocates for making it easier to run early stage clinical trials in the U.S. and for it to be less costly for small biotech companies to engage with FDA. Chapters The economic impact of biotech - 1:28 Global competition
Sep 2
Two fathers of children with rare diseases talk about starting biotech companies to try to create new therapies for their family members and others
Interviewed by MassBio CEO Kendalle Burlin O'Connell, Ilan Ganot describes co-founding Solid Biosciences in honor of his child with Duchenne muscular dystrophy and Daniel Fischer discusses co-founding Tevard Biosciences in honor of his child with Dravet syndrome. Chapters Intros - 1:11 Ilan Ganot | Starting a DMD company - 6:17 Daniel Fischer | Starting a Dravet company - 8:39 The Massachusetts ecosystem - 10:36 Being a CEO - 18:48 Advice for other parents - 23:43 Incentivizi
Aug 26
MassBio's 2026 Industry Snapshot shows a biotech sector that has been accelerating this year, but warning signs about early stage company building and investments should be given close attention
MassBio CEO Kendalle Burlin O'Connell highlights key findings of the report, including that employment in life sciences was down in 2025 for the first time in decades, and suggests that we should be both optimistic about the current state of the sector but mindful to make seed investments to keep it up over the longer term. Download the Report
Aug 25
The Zayed Centre for Research into Rare Disease in Children at Great Ormond Street Hospital (GOSH) in London has already been at the cutting edge of new technologies since it opened in 2019
Aofie Regan, Director of Charitable Programmes and Impact at GOSH's Children's Charity, describes the research that happens there, which is transparently on display for the public to see from the street. In addition to do work directly there that might not be driven forward on its own, they also recently initiated a clinical trials funding programme.
Jul 8
BIO 2026: Sofinnova Investments' Managing Partner Jim Healy shares his (optimistic) take on the current state of biotech and the venture side of it
He says he sees generalist investors coming back to biotech for the first time in a while, which have been benefitting the IPO market and other areas of the sector. Plus, the areas he is focused on today and what it take to be a successful IPO candidate. Coverage brought to you by
Jun 22
.png){kind=logo}